Bio-Techne has consolidated its products and technologies under a streamlined brand architecture comprising three distinct portfolios: R&D Systems, Bio-Techne Spatial and Bio-Techne Diagnostics. This reorganization aligns each portfolio with key stages of the scientific journey, from early discovery and translational research to clinical decision-making.

R&D Systems centralizes high-quality proteins, antibodies, small molecules and analytical instruments for reproducible early-stage research and GMP-grade reagents for cell and gene therapy workflows. Bio-Techne Spatial integrates RNAscope in situ hybridization and COMET spatial hyperplex platforms for high-resolution multiomic analysis. Bio-Techne Diagnostics offers IVD-grade reagents, assay kits, calibrators and proficiency-testing materials for reliable clinical assay development and deployment.

The three portfolio brands will debut at the AACR Annual Meeting 2026 in San Diego and at IMMUNOLOGY2026™ in Boston, where Bio-Techne will showcase aligned solutions designed to accelerate research workflows. Attendees can explore product demonstrations and engage with technical experts on the end-to-end scientific and diagnostic pathway.

By clarifying its brand structure, Bio-Techne aims to enhance customer access to targeted solutions and reinforce its position as a partner in scientific and clinical innovation. The rebranding supports the company’s broader mission to drive advances in life sciences, building on its global presence of 34 locations, 3,100 employees and $1.2 billion in net sales for fiscal 2025.